

Company name Bsense Bio Therapeutics Ltd - * Website <https://www.bsense-bio.com/>
* CEO name Dori Pelled, PhD

CATEGORY: Biotech/Pharma Select one SESSION per abstract from the list below *

“Beyond Neuropharma and Neurotech: Integrated Brain Control.” • Executive Summary / Investment Rational: Bsense develops a novel, oral, first-in-class, nonopioid approach to treat chronic pain. BSEN760, was selected for the NIH - HEAL Initiative. Chronic pain is a massive unmet need, affecting tens of millions of patients and carrying a huge economic and social burden. Current treatment options, opioids, NSAIDs, anticonvulsants, often fall short due to limited efficacy & tolerability issues. • Core Technology: Bsense developed a drug candidate that selectively suppresses hyperexcitable peripheral sensory neurons by dual-modulation of two validated ion-channel pain targets, voltage-gated type 7 potassium channels, Kv7.2/3 and cation channel, transient receptor potential vanilloid 1 (TRPV1). Technology was invented by Prof. Bernard Attali to improve analgesia while reducing systemic liabilities that constrained earlier programs targeting each ion-channel individually. • Product Profile/Pipeline: BSEN760 therapy for chronic pain has shown efficacy across multiple preclinical pain models, while overcoming biological redundancy that limits the effectiveness of current single-target pain therapies, especially in the non-opioid marketplace. Furthermore, BSEN760 outperformed naproxen in an osteoarthritis pain model and matched pregabalin's efficacy in a neuropathic pain model — without sedation or motor impairment, hyperthermia or impact on heat sensation. • Business Strategy: Bsense applies its dual-ion-channel mechanism to develop differentiated non-opioid pain therapeutics aligned with clinically validated ion-channel targets. There is a strong wave of regulatory, clinical, and investor momentum in the non-opioid pain space. Thus, Bsense seeks to generate early clinical data to enable progression into Phase 2 development through partnership or internal advancement. • What's Next? The company received a positive response from the FDA for its Pre-IND submission of BSEN760. Next steps focus on completing IND-enabling nonclinical studies and development of Investigational Medicinal Product (IMP) for BSEN760 to support the IND filing and to initiate first-in-human trials, Single Ascending Dose/Multiple Ascending Dose (SAD/MAD) Phase 1a clinical trial in healthy volunteers